What are the side effects of VIP (Vasoactive Intestinal Peptide)?
The most commonly reported VIP (Vasoactive Intestinal Peptide) side effects are mild flushing, injection-site reaction (if sub-q), rare: hypotension at high doses. Most are mild and tend to be dose dependent. It is generally avoided with hypotension or unstable cardiovascular status. Human clinical evidence for VIP (Vasoactive Intestinal Peptide) is limited, so this reflects reported and observed effects, not a complete safety profile.
Reported VIP (Vasoactive Intestinal Peptide) side effects
- Mild flushing
- Injection-site reaction (if sub-q)
- Rare: hypotension at high doses
Who should avoid it
- Hypotension or unstable cardiovascular status
- Pregnancy / nursing
- CIRS protocol specifically requires baseline biotoxin clearance first
Bloodwork worth tracking
- MMP-9, C4a, TGF-β1 in CIRS context (Shoemaker panel)
References
- Vasoactive intestinal peptide (VIP) and inflammation, review — Delgado M & Ganea D, Amino Acids, 2013
- Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells — Sun X et al., World Journal of Gastroenterology, 2020
- Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis — Eger M et al., Frontiers in Pharmacology, 2021
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on VIP (Vasoactive Intestinal Peptide)
Last updated 2026-06-06.